Fabry disease plaintiffs who can’t link specific harm to a shortage of the branded drug Fabrazyme can’t pursue would-be class suits against maker Genzyme Corp., a federal appeals court said May 23 (Hochendoner v. Genzyme Corp., 2016 BL 163452, 1st Cir, 15-1446, 5/23/16).
Manufacturing problems led to shortages from 2009 until 2012 and a rationing plan under which U.S. patients were allocated less than the approved Fabrazyme dose.
Anita Hochendoner and Philip Adamo filed class complaints against Genzyme that were dismissed by the U.S. District Court for the District of Massachusetts30 TXLR 340, 4/2/15, 09 LSLR 361, 4/3/15, 13 PLIR 459, 4/3/15, 43 PSLR 443, 4/6/15, 16 CLASS 402, 4/10/15
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.